The treatment of schizophrenia has been focused on modulation of dopamine receptors for over 50 years. Recent
developments have implicated other neurotransmitter systems in the pathophysiology of this illness. The discovery
and characterization of glutamate receptors and their roles in the brain has lead to novel approaches for the treatment of
schizophrenia. In this article, we review drugs that modulate ionotropic gluamate receptors and discuss their efficacy for
the treatment of this often debilitating severe mental illness.
Keywords: Schizophrenia, glutamate, NMDA, AMPA, kainate, glycine, D-serine, lamotrigene, dopamine receptors, neurotransmitter systems, athophysiology, glutamate receptors, novel approaches, ionotropic gluamate receptors
Rights & PermissionsPrintExport